$60.50 -0.02 (%) AbbVie Inc - NYSE

Feb. 27, 2015 | 04:00 PM

Partner Headlines

  1. Cyberonics Soars On Earnings Beat, Tax Inversion Deal

    IBD | Feb. 26, 2015 | 13:58PM EST
  2. Making Money With Charles Payne: 02/25/15

    FoxBusiness | Feb. 25, 2015 | 18:00PM EST
  3. Heavy News Day For Several Biotech Stocks

    Benzinga | Feb. 25, 2015 | 15:34PM EST
  4. Catalysts AbbVie Investors Need To Watch

    Benzinga | Feb. 24, 2015 | 18:28PM EST
  5. UPDATE: Results from AbbVie's Study of VIEKIRA PAK

    Benzinga | Feb. 23, 2015 | 11:05AM EST
  6. Results from AbbVie's Study of VIEKIRA PAK™ (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) in Chronic Hepat

    Benzinga | Feb. 23, 2015 | 11:05AM EST
  7. Evercore ISI Technical Analysis: The 'Single Best Idea'

    Benzinga | Feb. 23, 2015 | 07:34AM EST
  8. CNBC's Stock Pops & Drops From February 20

    Benzinga | Feb. 22, 2015 | 20:26PM EST
  9. Dogs Of The S&P 500 - No Dividend Alternatives Are Cheaper!

    GuruFocus | Feb. 21, 2015 | 22:55PM EST
  10. Jefferies Names AbbVie As Top Pharmaceutical Pick, Offers Alternative Choices

    Benzinga | Feb. 20, 2015 | 13:10PM EST
  11. Soros Fund Management Sells American Express & Netflix, Buys FireEye In Q4

    Benzinga | Feb. 17, 2015 | 17:25PM EST
  12. Biotech Performance 'Particularly Impressive,' Says JP Morgan

    Benzinga | Feb. 17, 2015 | 13:30PM EST
  13. Salix, Top Drug Stocks Rally As Merger Mania Heats Up

    IBD | Feb. 13, 2015 | 18:08PM EST
  14. Shire Moves Higher On NPS Potential; Q4 Earnings Miss

    IBD | Feb. 12, 2015 | 10:45AM EST
  15. US Stock Futures Up Ahead Of Jobless Claims, Retail Sales Data

    Benzinga | Feb. 12, 2015 | 07:30AM EST
  16. Deutsche Bank's 7 Reasons AbbVie Is Still A Buy

    Benzinga | Feb. 11, 2015 | 12:54PM EST
  17. Achillion Pharmaceuticals Stock Soars Following Successful Mid-Stage Hep C Drug Combo Trial

    GuruFocus | Feb. 10, 2015 | 12:36PM EST
  18. Jefferies Analyst Says AbbVie Hepatitis C Price-War Fears Overblown

    Benzinga | Feb. 9, 2015 | 11:46AM EST
  19. UPDATE: Citi Initiates Coverage On AbbVie, Sees Price Erosion Ahead

    Benzinga | Feb. 9, 2015 | 09:45AM EST
  20. Benzinga's Top Initiations

    Benzinga | Feb. 9, 2015 | 09:25AM EST
  21. Citigroup Initiates AbbVie With Sell

    Benzinga | Feb. 9, 2015 | 08:38AM EST
  22. Barron's Recap: This Man Made, Lost And Made A Fortune Investing In Russia

    Benzinga | Feb. 8, 2015 | 11:09AM EST
  23. Andreas Halvorsen's Trades Of January 2015

    GuruFocus | Feb. 6, 2015 | 11:25AM EST
  24. Gilead Sciences Offering Fresh Wave Of Competition To AbbVie's Viekira Pak

    GuruFocus | Feb. 6, 2015 | 10:59AM EST
  25. Gilead Sciences Falls 10% After More Than Doubling Drug Discounts For 2015

    GuruFocus | Feb. 5, 2015 | 11:35AM EST
  26. Merck hep C drug faces delays

    IBD | Feb. 4, 2015 | 19:29PM EST
  27. Gilead

    IBD | Feb. 4, 2015 | 19:28PM EST
  28. HCV Stocks Struggle As Gilead, Merck Face Headwinds

    IBD | Feb. 4, 2015 | 12:12PM EST
  29. AbbVie's Q4 Reflects Its Tremendous Growth Potential Going Forward

    GuruFocus | Feb. 4, 2015 | 11:58AM EST
  30. Gilead Q4 Earnings Beat, But Price War Taking Toll

    IBD | Feb. 3, 2015 | 19:26PM EST
  31. Looking Ahead of Wall Street: Gilead Sciences, Chipotle, Twitter

    GuruFocus | Feb. 3, 2015 | 18:27PM EST
  32. UBS Thinks AbbVie's Valuation Is 'Interesting'

    Benzinga | Feb. 2, 2015 | 11:18AM EST
  33. Cramer Advises Viewers On Mattel, Linn Energy And AbbVie

    Benzinga | Feb. 1, 2015 | 12:57PM EST
  34. Viekira Pak View Falls Short

    IBD | Jan. 30, 2015 | 18:41PM EST
  35. What Investors Are Watching For In Regulus Therapeutics' Next Data Release

    Benzinga | Jan. 30, 2015 | 14:32PM EST
  36. AbbVie Beats, But Stock Falls; Lilly Cuts Guidance

    IBD | Jan. 30, 2015 | 13:29PM EST
  37. UPDATE: AbbVie Q4 Earnings Beat Views

    Benzinga | Jan. 30, 2015 | 08:39AM EST
  38. Earnings Scheduled For January 30, 2015

    Benzinga | Jan. 30, 2015 | 04:57AM EST
  39. Baird Remains Buyers Of Gilead Before Earnings Release

    Benzinga | Jan. 29, 2015 | 14:18PM EST
  40. Fast Money Halftime Report Final Trade From January 28

    Benzinga | Jan. 29, 2015 | 06:24AM EST
  41. AmerisourceBergen Hits New High On Earnings, Outlook

    IBD | Jan. 28, 2015 | 13:45PM EST
  42. Gilead Sciences Still has More Upside

    GuruFocus | Jan. 22, 2015 | 15:28PM EST
  43. Has Gilead Sciences Been Able To Maintain Its Lead Run In The Face Of Competition?

    GuruFocus | Jan. 22, 2015 | 12:32PM EST
  44. Hep C price cuts a concern

    IBD | Jan. 21, 2015 | 18:42PM EST
  45. Deutsche Bank Comments On Concerns Over Consensus Estimates For AbbVie And Gilead Sciences

    Benzinga | Jan. 21, 2015 | 16:27PM EST
  46. Gilead, AbbVie Hepatitis C Price Cuts Will Hit Sales

    IBD | Jan. 21, 2015 | 12:55PM EST
  47. J&J Earnings Beat, But Sales, Guidance Miss Estimates

    IBD | Jan. 20, 2015 | 11:20AM EST
  48. Aetna Sides With Gilead In Hepatitis C Drug Battle

    IBD | Jan. 16, 2015 | 15:43PM EST
  49. Shire Set To Acquire NPS Pharmaceuticals for $5.2 Billion

    GuruFocus | Jan. 15, 2015 | 14:29PM EST
  50. Eli Lilly Has 'Turned The Corner,' Upgraded

    IBD | Jan. 15, 2015 | 11:02AM EST
Trading Center